Cargando…
Development and characterization of anti-SARS-CoV-2 intravenous immunoglobulin from COVID-19 convalescent plasma
Background: The authors describe the developmental process of intravenous anti-COVID-19 hyperimmune immunoglobulin from anti-SARS-CoV-2 neutralizing antibody-containing plasma. Furthermore, the authors investigated its safety and protective activity in animal models. Materials & methods: The man...
Autores principales: | Razumikhin, Mikhail, Smolyanova, Tatiana, Nikolaeva, Alevtina, Orlova, Ekaterina, Ivanov, Aleksandr, Belyakova, Olga, Vyaznikova, Tatyana, Selezneva, Natalia, Perevozchikov, Anton, Sokolova, Alina, Zubkova, Nataliya, Efimova, Irina, Dolzhikova, Inna, Logunov, Denis, Sakanjan, Elena |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Future Medicine Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9328115/ https://www.ncbi.nlm.nih.gov/pubmed/35892311 http://dx.doi.org/10.2217/imt-2022-0015 |
Ejemplares similares
-
Data discrepancies and substandard reporting of interim data of Sputnik V phase 3 trial – Authors' reply
por: Logunov, Denis Y, et al.
Publicado: (2021) -
Safety and efficacy of the Russian COVID-19 vaccine: more information needed – Authors’ reply
por: Logunov, Denis Y, et al.
Publicado: (2020) -
Genetic Passive Immunization with Adenoviral Vector Expressing Chimeric Nanobody-Fc Molecules as Therapy for Genital Infection Caused by Mycoplasma hominis
por: Burmistrova, Daria A., et al.
Publicado: (2016) -
Convalescent plasma (hyperimmune immunoglobulin) for COVID-19 management: An update
por: Chavda, Vivek P., et al.
Publicado: (2023) -
A Randomized Controlled Study Assessing Convalescent Immunoglobulins vs Convalescent Plasma for Hospitalized Patients With Coronavirus 2019
por: Maor, Yasmin, et al.
Publicado: (2023)